Renal effects of urodilatin in healthy subjects are independent of blockade of the cyclooxygenase and angiotensin II receptor.

What Was Tested

Researchers studied Indomethacin and Losartan in this randomized controlled trial publication.

Little is known about the role of the renin-angiotensin-aldosterone system and the renal prostaglandins in modulating the renal vasoconstrictive and natriuretic effects of synthetic urodilatin (URO) in healthy humans.

Who Took Part

The abstract describes 12 subjects taking part.

PubMed indexes the participants as adults, men only.

All subjects received a URO infusion (15 ng kg(-1) min(-1)) on day 5.

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and crossover.

Because people in this Indomethacin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Indomethacin study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Indomethacin group a baseline to be compared against.

In the crossover set-up each of the subjects took both Indomethacin and the comparison in turn, acting as their own control.

Radioactive tracers and the lithium clearance technique were used.

What Was Measured

The subject headings attached to it are Aldosterone, Angiotensin Receptor Antagonists, Atrial Natriuretic Factor, Blood Pressure, Cyclic GMP, Diuresis and Diuretics.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Indomethacin and Losartan in 12 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Scandinavian journal of clinical and laboratory investigation), a journal based in England.

More context: all human trials.